The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Debio 0123, a highly selective WEE1 inhibitor in adult patients with advanced solid tumors: A phase 1 dose escalation and expansion monotherapy study.
 
Maria Rubinstein
Honoraria - MJH Life Sciences; OncLive/MJH Life Sciences
Research Funding - ASCO (Inst); AstraZeneca (Inst); Debiopharm Group (Inst); Duality Biologics (Inst); Faeth Therapeutics (Inst); Merck (Inst); Summit Therapeutics (Inst)
 
Manish Sharma
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Amgen; Bristol-Myers Squibb; Gilead Sciences; Johnson & Johnson/Janssen; Lilly; Merck; Moderna Therapeutics; Regeneron; Vertex; West Pharmaceutical
Consulting or Advisory Role - AADi; Enlaza Therapeutics; Pliant
Research Funding - Abbvie (Inst); Adcentrx Therapeutics (Inst); Agenus (Inst); Alkermes (Inst); Alpine Immune Sciences (Inst); ALX Oncology (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Boundless Bio Therapeutics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Chugai Pharma (Inst); Compugen (Inst); Cullinan Oncology (Inst); Debiopharm Group (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); Elevation Oncology (Inst); Exelixis (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline/Tesaro (Inst); Helsinn Therapeutics (Inst); IgM Biosciences (Inst); Ikena Oncology (Inst); Incyte (Inst); InhibRx (Inst); Johnson & Johnson/Janssen (Inst); Johnson & Johnson/Janssen (Inst); Jounce Therapeutics (Inst); Kinnate Biopharma (Inst); KLUS Pharma (Inst); KSQ Therapeutics (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Onconova Therapeutics (Inst); Palleon Pharmaceuticals (Inst); Pfizer (Inst); Pliant (Inst); PureTech (Inst); Qualigen Therapeutics (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Seven and Eight Biopharmaceuticals (Inst); Shattuck Labs (Inst); SK Life Sciences (Inst); Symphogen (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Theratechnologies (Inst); Tizona Therapeutics, Inc. (Inst); Treadwell Therapeutics (Inst)
 
Kyriakos Papadopoulos
Consulting or Advisory Role - AADi; Turning Point Therapeutics
Research Funding - 3D Medicines (Inst); Abbvie (Inst); Alnylam (Inst); Amgen (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Biontech (Inst); Bristol-Myers Squibb/Celgene (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); F-star (Inst); Frontier Medicines (Inst); Genmab (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Kezar Life Sciences (Inst); Lilly (Inst); Linnaeus Therapeutics (Inst); MabSpace Biosciences (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Parabilis Medicines (Inst); Pfizer (Inst); PharmaMar (Inst); Regeneron (Inst); Revolution Medicines (Inst); Sensei Biotherapeutics (Inst); Storm Therapeutics (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Treadwell Therapeutics (Inst)
 
Maria-Pilar Barretina-Ginesta
Consulting or Advisory Role - Abbvie; AstraZeneca; Clovis Oncology; Eisai Europe; GlaxoSmithKline; MSD Oncology; Pharma&; PharmaMar; Regeneron
Speakers' Bureau - Abbvie; AstraZeneca Spain; Eisai Europe; GlaxoSmithKline; MSD Oncology; Regeneron
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; MSD Oncology
 
Carmen García-Duran
Consulting or Advisory Role - Eisai Farmaceutica S.A.; MSD Oncology
Speakers' Bureau - AstraZeneca Spain; GlaxoSmithKline
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline
 
Mariano Ponz-Sarvise
Consulting or Advisory Role - Ability Pharma; AstraZeneca Spain; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Novocure (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - AstraZeneca (Inst); Incyte; Oncosil
 
Andres Redondo
Consulting or Advisory Role - Abbvie; AstraZeneca; Eisai; GlaxoSmithKline; MSD; Pharma&
Speakers' Bureau - Abbvie; AstraZeneca; GlaxoSmithKline; MSD; pharma&
Travel, Accommodations, Expenses - AstraZeneca
 
Victor Moreno
Employment - START
Consulting or Advisory Role - Abbvie; Affimed Therapeutics; AstraZeneca; Basilea; Bayer; BMS; Ellipses Pharma; Janssen Oncology; Merck; Roche
Speakers' Bureau - Bayer; Pierre Fabre
Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Adaptimmune (Inst); ADC Therapeutics (Inst); Amgen (Inst); Ascendis Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Bioinvent (Inst); Biomea Fusion (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Crescendo Bioscience (Inst); Cullinan Oncology (Inst); E-therapeutics (Inst); Eisai (Inst); F-Star Biotechnology (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Grey Wolf Therapeutics (Inst); hemavant (Inst); HiFiBiO Therapeutics (Inst); Janssen (Inst); Kinnate Biopharma (Inst); Menarini (Inst); Merck (Inst); MonTa Biosciences (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Revolution Medicines (Inst); RigonTEC (Inst); Roche (Inst); Sanofi (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Transgene (Inst)
Expert Testimony - Medscape/Bayer; Nanobiotix
Travel, Accommodations, Expenses - Sanofi/Regeneron
Other Relationship - BMS
 
Denise Uyar
No Relationships to Disclose
 
Julian Wampfler
No Relationships to Disclose
 
Dagmar Hess
Stock and Other Ownership Interests - Bayer; Novartis (I); Roche (I)
 
Luis Manso
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Lilly; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Tesaro
Speakers' Bureau - AstraZeneca; Lilly; Novartis; Pfizer; Roche/Genentech
Research Funding - Tesaro
Travel, Accommodations, Expenses - GlaxoSmithKline; MSD Oncology; Novartis; Roche/Genentech; Tesaro
 
Jeannette Fuchs
Employment - Debiopharm Group
 
Emmelyne Dessein Corne
Employment - Debiopharm International S.A.
 
Noemie Luong
Employment - Debiopharm Group
Travel, Accommodations, Expenses - Debiopharm Group
 
Vito Dozio
Employment - Debiopharm Group
 
Tri Tat
Employment - Debiopharm Group
Consulting or Advisory Role - Debiopharm Group
 
Francoise Crevel
Employment - Debiopharm Group
 
Victor Rodriguez Freixinos
Employment - Debiopharm Group; GlaxoSmithKline (I)
Travel, Accommodations, Expenses - Debiopharm Group; GlaxoSmithKline (I); GlaxoSmithKline (I)
 
Anastasios Stathis
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); Debiopharm Group (Inst); Incyte; Incyte (Inst); Janssen Oncology (Inst); Loxo/Lilly (Inst); Novartis (Inst); Roche (Inst)
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); BMS GmbH & Co. KG (Inst); BMS GmbH & Co. KG (Inst); Cellestia Biotech (Inst); Debiopharm Group (Inst); Incyte (Inst); Lilly (Inst); Loxo (Inst); MEI Pharma (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Philogen (Inst); Prelude Therapeutics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Incyte (Inst)